Clinical Trial

Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Dimensions: NCT03440372

Investigators

Affiliations

Organisations

  1. (1) Bristol-Myers Squibb (United States), grid.419971.3

Sponsors/collaborators

Abstract

This is a Phase 3, randomized, double-blind, placebo-controlled study to explore the effect of oral ozanimod as an induction treatment for subjects with moderately to severely active Crohn's Disease.

Methods

Condition: Crohn Disease

Intervention: Placebo

Recruitment information

Gender: All

Trial period

2018-2023

Phase

Phase 3

Research Categories

Main Subject Area

Fields of Research

External sources

Access at Registry